About   Help   FAQ
Due to maintenance, access to MGI may be intermittent 8:00 AM ET Wed, September 18.
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Gt(ROSA)26Sortm9(cre/ESR1)Arte
targeted mutation 9, TaconicArtemis
MGI:3763211
Summary 44 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Gt(ROSA)26Sortm1Iaai/Gt(ROSA)26Sortm9(cre/ESR1)Arte involves: C57BL/6 * C57BL/6NTac MGI:5496424
cn2
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl MGI:5525144
cn3
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Epas1tm1Mcs/Epas1tm1Mcs
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Epas1tm1Mcs MGI:5525147
cn4
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Hif1atm3Rsjo/Hif1atm3Rsjo
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Hif1atm3Rsjo MGI:5525146
cn5
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte P2ry6tm1Jabo MGI:5304918
cn6
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pcgf5tm1.1Aiwa/Pcgf5tm1.1Aiwa
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Pcgf5tm1.1Aiwa MGI:6118943
cn7
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Map3k14tm1.1Gne/Map3k14tm1.1Gne
B6(Cg)-Map3k14tm1.1Gne Gt(ROSA)26Sortm9(cre/ESR1)Arte MGI:5903230
cn8
Mcl1tm1Dmta/Mcl1tm1Dmta
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte MGI:4840320
cn9
Mcl1tm1Dmta/Mcl1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte MGI:4840321
cn10
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac MGI:5304917
cn11
Slc34a2tm1.1Scc/Slc34a2tm1.1Scc
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac MGI:4847571
cn12
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129 * C57BL/6 * C57BL/6NTac * SJL MGI:5551813
cn13
Kmt2btm1Afst/Kmt2btm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 MGI:4867495
cn14
Espl1tm1.1Kna/Espl1tm1.2Kna
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac * SJL MGI:5551815
cn15
Kdm6atm1.1Afst/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac MGI:5499566
cn16
Kdm6atm1.1Afst/Kdm6atm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac MGI:5499565
cn17
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6 MGI:5008585
cn18
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6 MGI:5008587
cn19
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
Tnfaip3tm1Homy/Tnfaip3tm1Homy
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac MGI:5698269
cn20
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Rnf2tm1Mvi/Rnf2tm1Mvi
involves: 129S/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:4413348
cn21
Pkd1tm1Gztn/Pkd1tm1Gztn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * 129S7/SvEvBrd * C57BL/6 MGI:4819716
cn22
Chuktm1Lex/Chuktm1Lex
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * 129S/SvEvBrd * C57BL/6 MGI:5551391
cn23
Epotm1Knni/Epotm1Knni
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * C57BL/6 MGI:4839528
cn24
Ezh2tm1Yugo/Ezh2tm1Yugo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: 129S/Sv * C57BL/6 MGI:4413346
cn25
Foxl2tm2.1Tre/Foxl2tm2.1Tre
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
involves: 129S/Sv * C57BL/6 MGI:4430332
cn26
Nodaltm1.1Ysa/Nodaltm1.1Ysa
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5462060
cn27
Sptlc2tm1Yhir/Sptlc2tm1Yhir
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5523516
cn28
Sh2d1atm2.1Cpt/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5444639
cn29
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5547377
cn30
Bap1tm1.1Geno/Bap1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5439659
cn31
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5439657
cn32
Cbx8tm1Hko/Cbx8tm1Hko
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5306649
cn33
Ciao3tm1.1Fsl/Ciao3tm1.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:4946835
cn34
Eef1a1tm2Arge/Eef1a1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5496427
cn35
Cd28tm1.1Huen/Cd28tm1.1Huen
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5461543
cn36
Sh2d1atm2.1Cpt/Sh2d1atm2.1Cpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5444641
cn37
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac MGI:5502351
cn38
Hsp90aa1tm1.2Udon/Hsp90aa1tm1.2Udon
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6 * C57BL/6NTac * FVB/N MGI:5441571
cn39
Ddx5tm1.1Arte/Ddx5tm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6N * C57BL/6NTac MGI:5464119
cn40
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pkn2tm1c(KOMP)Wtsi/Pkn2tm1c(KOMP)Wtsi
involves: C57BL/6N * C57BL/6NTac MGI:5912012
cn41
Pi4katm1.1Arte/Pi4katm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac MGI:5444174
cn42
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ripk3tm1Arte/Ripk3tm1Arte
involves: C57BL/6NTac MGI:5614626
cn43
Pi4katm2.1Arte/Pi4ka+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac MGI:5444176
cn44
Pi4katm2.1Arte/Pi4katm2.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
involves: C57BL/6NTac MGI:5444175


Genotype
MGI:5496424
cn1
Allelic
Composition
Gt(ROSA)26Sortm1Iaai/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1Iaai mutation (0 available); any Gt(ROSA)26Sor mutation (497 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• hematopoietic stem and progenitor cells (HSPCs) infected with MLL-AF9 and transplanted in lethally irradiated recipients treated with tamoxifen produce fewer white blood cells compared with control cells
• bone marrow HSPCs infected with MLL-AF9 or AML1-ETO and treated with tamoxifen exhibit reduced colony number and loss of blast colony morphology unlike control cells




Genotype
MGI:5525144
cn2
Allelic
Composition
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm2.1Fsl mutation (0 available); any Egln1 mutation (12 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• following treatment with tamoxifen, extramedullary hematopoiesis is observed in spleens
• following treatment with tamoxifen, mice exhibit erythrocytosis
• following treatment with tamoxifen, mice exhibit hematocrits close to 80%
• following treatment with tamoxifen

homeostasis/metabolism
• following treatment with tamoxifen, mice exhibit increased serum erythropoietin levels

immune system
• following treatment with tamoxifen

mortality/aging
• following treatment with tamoxifen




Genotype
MGI:5525147
cn3
Allelic
Composition
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Epas1tm1Mcs/Epas1tm1Mcs
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Epas1tm1Mcs
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm2.1Fsl mutation (0 available); any Egln1 mutation (12 available)
Epas1tm1Mcs mutation (1 available); any Epas1 mutation (45 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• hematocrit level, erythropoietin level and spleen architecture and weight are similar to mice without cre/ESR1 allele
• the Epas1 allele functions to rescue the erythrocytosis phenotype

mortality/aging
• survival is improved relative to mice carrying the Egln1 null allele, but not to control levels




Genotype
MGI:5525146
cn4
Allelic
Composition
Egln1tm2.1Fsl/Egln1tm2.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Hif1atm3Rsjo/Hif1atm3Rsjo
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Egln1tm2.1Fsl Hif1atm3Rsjo
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Egln1tm2.1Fsl mutation (0 available); any Egln1 mutation (12 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Hif1atm3Rsjo mutation (3 available); any Hif1a mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• following treatment with tamoxifen, extramedullary hematopoiesis is observed in spleens
• following treatment with tamoxifen, mice exhibit hematocrits close to 80%
• following treatment with tamoxifen

homeostasis/metabolism
• following treatment with tamoxifen, mice exhibit increased serum erythropoietin levels

immune system
• following treatment with tamoxifen

mortality/aging
• following treatment with tamoxifen, however, survival is improved relative to tamoxifen treated Egln1tm2.1Fsl mice alone




Genotype
MGI:5304918
cn5
Allelic
Composition
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte P2ry6tm1Jabo
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
P2ry6tm1Jabo mutation (0 available); any P2ry6 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• following exposure to Dermatophagoides farinae, tamoxifen-treated mice exhibit increased total cells in the bronchioalveolar fluid (5-fold increase in eosinophils and neutrophils), increased goblet cell metaplasia, and increased cytokine secretion (IL4, IL5, IL13, and IFN-gamma) compared with control mice

respiratory system
• following exposure to Dermatophagoides farinae, tamoxifen-treated mice exhibit increased total cells in the bronchioalveolar fluid (5-fold increase in eosinophils and neutrophils), increased goblet cell metaplasia, and increased cytokine secretion (IL4, IL5, IL13, and IFN-gamma) compared with control mice
• following exposure to Dermatophagoides farinae in tamoxifen-treated mice

hematopoietic system
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice




Genotype
MGI:6118943
cn6
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pcgf5tm1.1Aiwa/Pcgf5tm1.1Aiwa
Genetic
Background
B6.Cg-Gt(ROSA)26Sortm9(cre/ESR1)Arte Pcgf5tm1.1Aiwa
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pcgf5tm1.1Aiwa mutation (0 available); any Pcgf5 mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• bone marrow cells treated with tamoxifen exhibit normal reconstitution capacity hematopoiesis




Genotype
MGI:5903230
cn7
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Map3k14tm1.1Gne/Map3k14tm1.1Gne
Genetic
Background
B6(Cg)-Map3k14tm1.1Gne Gt(ROSA)26Sortm9(cre/ESR1)Arte
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Map3k14tm1.1Gne mutation (0 available); any Map3k14 mutation (24 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction

immune system
N
• after tamoxifen treatment of adult mice
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction
• in mesenteric lymph nodes and Peyers patches reductions in total B cells occurred as early as days 512 post-tamoxifen treatment, with further reductions occurring through the last time point examined at day 30 post-tamoxifen
• in mesenteric lymph nodes and Peyers patches
• severe reduction
• modest reduction
• modest reduction

hematopoietic system
• reduced response to Tnfsf13b in vitro 2 days, and in vivo 3 and 5 days after tamoxifen treatment
• lack of BrdU incorporation after Tnfsf13b induction in vivo 3 and 5 days after tamoxifen treatment
• proliferation in response to anti-Cd40 or anti-Ighm antibody induction
• in mesenteric lymph nodes and Peyers patches reductions in total B cells occurred as early as days 512 post-tamoxifen treatment, with further reductions occurring through the last time point examined at day 30 post-tamoxifen
• in mesenteric lymph nodes and Peyers patches
• severe reduction
• modest reduction
• modest reduction




Genotype
MGI:4840320
cn8
Allelic
Composition
Mcl1tm1Dmta/Mcl1tm1Dmta
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Mcl1tm1Dmta mutation (0 available); any Mcl1 mutation (30 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• when bone marrow cells are used to reconstitute lethally irradiated mice, NP-KLH and tamoxifen treated chimeras exhibit a reduction in IgM+ plasma blasts cells compared to when wild-type bone marrow are used
• following tamoxifen-treatment and immunization with NP-KLH
• following tamoxifen-treatment and immunization with NP-KLH
• greater than 5-fold following tamoxifen-treatment

hematopoietic system
• when bone marrow cells are used to reconstitute lethally irradiated mice, NP-KLH and tamoxifen treated chimeras exhibit a reduction in IgM+ plasma blasts cells compared to when wild-type bone marrow are used
• following tamoxifen-treatment and immunization with NP-KLH
• following tamoxifen-treatment and immunization with NP-KLH
• greater than 5-fold following tamoxifen-treatment




Genotype
MGI:4840321
cn9
Allelic
Composition
Mcl1tm1Dmta/Mcl1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
B6.Cg-Mcl1tm1Dmta Gt(ROSA)26Sortm9(cre/ESR1)Arte
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Mcl1tm1Dmta mutation (0 available); any Mcl1 mutation (30 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• following tamoxifen-treatment and immunization with NP-KLH
• following tamoxifen-treatment and immunization with NP-KLH

hematopoietic system
• following tamoxifen-treatment and immunization with NP-KLH
• following tamoxifen-treatment and immunization with NP-KLH




Genotype
MGI:5304917
cn10
Allelic
Composition
P2ry6tm1Jabo/P2ry6tm1Jabo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129 * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
P2ry6tm1Jabo mutation (0 available); any P2ry6 mutation (10 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• the percentage of polyclonally stimulated apoptotic CD4+ T cells of the parabronchial lymph node from tamoxifen-treated is decreased compared to in control mice
• the percentage of polyclonally stimulated proliferating CD4+ T cells of the parabronchial lymph node or spleen from tamoxifen-treated is increased compared to in control mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• following exposure to Dermatophagoides farinae in tamoxifen-treated mice

immune system
• the percentage of polyclonally stimulated apoptotic CD4+ T cells of the parabronchial lymph node from tamoxifen-treated is decreased compared to in control mice
• the percentage of polyclonally stimulated proliferating CD4+ T cells of the parabronchial lymph node or spleen from tamoxifen-treated is increased compared to in control mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in the bronchioalveolar following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• following exposure to Dermatophagoides farinae in tamoxifen-treated mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• in CD3+/CD4+ T cells from tamoxifen-treated Dermatophagoides farinae-exposed mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• in CD3+/CD4+ T cells from tamoxifen-treated Dermatophagoides farinae-exposed mice
• in restimulated cells from the parabronchial lymph node or splenocytes of tamoxifen-treated Dermatophagoides farinae-exposed mice
• in CD3+/CD4+ T cells from tamoxifen-treated Dermatophagoides farinae-exposed mice
• following exposure to Dermatophagoides farinae, tamoxifen-treated mice exhibit increased total cells in the bronchioalveolar fluid (5-fold increase in eosinophils and neutrophils), increased goblet cell metaplasia, and increased cytokine secretion (IL4, IL5, IL13, and IFN-gamma) compared with control mice

respiratory system
• following exposure to Dermatophagoides farinae, tamoxifen-treated mice exhibit increased total cells in the bronchioalveolar fluid (5-fold increase in eosinophils and neutrophils), increased goblet cell metaplasia, and increased cytokine secretion (IL4, IL5, IL13, and IFN-gamma) compared with control mice
• following exposure to Dermatophagoides farinae in tamoxifen-treated mice

cellular
• the percentage of polyclonally stimulated apoptotic CD4+ T cells of the parabronchial lymph node from tamoxifen-treated is decreased compared to in control mice
• the percentage of polyclonally stimulated proliferating CD4+ T cells of the parabronchial lymph node or spleen from tamoxifen-treated is increased compared to in control mice




Genotype
MGI:4847571
cn11
Allelic
Composition
Slc34a2tm1.1Scc/Slc34a2tm1.1Scc
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129 * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Slc34a2tm1.1Scc mutation (0 available); any Slc34a2 mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
homeostasis/metabolism
• in tamoxifen-treated mice
• greater than 2-fold in tamoxifen-treated mice due to reduced intestinal absorption
• however, kidney function is normal
• tamoxifen-treated mice fail to exhibit a change in phosphorus in response to nicotinamide unlike similarly treated control mice

digestive/alimentary system
• tamoxifen-treated mice exhibit reduced intestinal absorption of phosphorus compared with similarly treated control mice
• tamoxifen-treated mice fail to exhibit a change in phosphorus in response to nicotinamide unlike similarly treated control mice
• tamoxifen-treated mice exhibit reduced sodium dependent intestinal phosphate transport in the jejunum and ileum compared with similarly treated control mice
• however, tamoxifen-treated mice exhibit normal calcium and sodium-independent phosphate transport
• after 10 week, tamoxifen-treated mice exhibit a 2-fold increase in focal phosphate content compared with similarly treated control mice

renal/urinary system
• in tamoxifen-treated mice
• greater than 2-fold in tamoxifen-treated mice due to reduced intestinal absorption
• however, kidney function is normal

respiratory system
• tamoxifen-treated mice develop calcification nodules in the lungs (pulmonary alveolar microlithiasis) unlike similarly treated control mice




Genotype
MGI:5551813
cn12
Allelic
Composition
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129 * C57BL/6 * C57BL/6NTac * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Wapltm1.1Jmpt mutation (0 available); any Wapl mutation (148 available)
Wapltm1.2Jmpt mutation (0 available); any Wapl mutation (148 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• impaired cell cycle progression in tamoxifen-treated mouse embryonic cells with improper chromosome segregation
• tamoxifen-treated mouse embryonic cells exhibit improper chromosome segregation
• in tamoxifen-treated mouse embryonic cells stimulated with serum




Genotype
MGI:4867495
cn13
Allelic
Composition
Kmt2btm1Afst/Kmt2btm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Kmt2btm1.1Afst mutation (0 available); any Kmt2b mutation (4 available)
Kmt2btm1Afst mutation (0 available); any Kmt2b mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• tamoxifen treatment provokes infertility in females regardless of genotype
• after treatment is discontinued, control animals fully recover fertility, whereas mutant females remain infertile




Genotype
MGI:5551815
cn14
Allelic
Composition
Espl1tm1.1Kna/Espl1tm1.2Kna
Wapltm1.1Jmpt/Wapltm1.2Jmpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NTac * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Espl1tm1.1Kna mutation (0 available); any Espl1 mutation (6 available)
Espl1tm1.2Kna mutation (0 available); any Espl1 mutation (6 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Wapltm1.1Jmpt mutation (0 available); any Wapl mutation (148 available)
Wapltm1.2Jmpt mutation (0 available); any Wapl mutation (148 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• tamoxifen-treated mouse embryonic fibroblasts exhibit diplo-chromosomes with unseparated arms unlike in control cells




Genotype
MGI:5499566
cn15
Allelic
Composition
Kdm6atm1.1Afst/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Kdm6atm1.1Afst mutation (0 available); any Kdm6a mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
N
• tamoxifen-treated mice exhibit normal blood counts




Genotype
MGI:5499565
cn16
Allelic
Composition
Kdm6atm1.1Afst/Kdm6atm1.1Afst
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Kdm6atm1.1Afst mutation (0 available); any Kdm6a mutation (38 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• in the spleen of tamoxifen-treated mice
• in tamoxifen-treated mice
• anemic appearance of the bones in tamoxifen-treated mice
• tamoxifen-treated mice exhibit disturbed cell distribution with pronounced dysplasia and disrupted maturation in the erythroid, megakaryocytic and granulocytic lineages compared with control mice
• bone marrow from tamoxifen-treated mice exhibit reduced formation of colony forming units compared with control mice
• however, tamoxifen-treated mice exhibit normal numbers of hematopoietic stem cells
• decreased granulocyte-macrophage progenitors and macrophage colony numbers from bone marrow of tamoxifen-treated mice
• abnormal nuclear lobation and atypical mitosis in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• dysplastic granulocytes with nuclear hyposegmentation in tamoxifen-treated mice
• in tamoxifen-treated mice
• in the spleen of tamoxifen-treated mice
• relative in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• impaired migration in hematopoietic stem and progenitor cells of tamoxifen-treated mice

cellular
• increased chromosomal double-strand breaks and numerical and structural chromosomal aberrations 2 weeks after tamoxifen-treatment

growth/size/body
• in tamoxifen-treated mice

skeleton
• anemic appearance of the bones in tamoxifen-treated mice

immune system
• dysplastic granulocytes with nuclear hyposegmentation in tamoxifen-treated mice
• in the spleen of tamoxifen-treated mice
• relative in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:5008585
cn17
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (39 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice survive 65 days compared with Pdk1tm1Dral Gt(ROSA)26Sortm9(cre/ESR1)Arte mice that survive 57

immune system
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice

neoplasm

behavior/neurological
• in tamoxifen-treated mice

hematopoietic system
• in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:5008587
cn18
Allelic
Composition
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte
Ptentm1Hwu/Ptentm1Hwu
Genetic
Background
involves: 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl mutation (0 available); any Gt(ROSA)26Sor mutation (497 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Ptentm1Hwu mutation (3 available); any Pten mutation (39 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice survive 57 days unlike control mice

immune system
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice

neoplasm
• tamoxifen-treated mice develop T cell acute lymphoblastic leukemia unlike control mice

behavior/neurological
• in tamoxifen-treated mice

growth/size/body
• in tamoxifen-treated mice

integument
• scruffy coat in tamoxifen-treated mice

hematopoietic system
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:5698269
cn19
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
Tnfaip3tm1Homy/Tnfaip3tm1Homy
Genetic
Background
involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Tnfaip3tm1Homy mutation (1 available); any Tnfaip3 mutation (28 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Microemboli and necrotic areas in Tnfaip3tm1Homy/Tnfaip3tm1Homy Gt(ROSA)26Sortm9(cre/ESR1)Arte/? liver

hematopoietic system
N
• no spontaneous development of abnormal phenotype
• marked drop in hematopoietic cell after tamoxifen administration

mortality/aging
• die within several days of tamoxifen administration

liver/biliary system
• microembolic and necrotic areas in the liver after tamoxifen administration (J:212681)
• with white spots after tamoxifen administration (J:212681)

cellular
• massive apoptosis in major organs after tamoxifen administration

immune system
• elevated levels of GM-CSF after tamoxifen administration
• particularly elevated after tamoxifen administration
• elevated after tamoxifen administration
• particularly elevated after tamoxifen administration
• particularly elevated TNF-alpha levels after tamoxifen administration

homeostasis/metabolism
• elevated levels of GM-CSF after tamoxifen administration
• particularly elevated after tamoxifen administration
• elevated after tamoxifen administration
• particularly elevated after tamoxifen administration
• particularly elevated TNF-alpha levels after tamoxifen administration
• die within several days of tamoxifen administration

endocrine/exocrine glands




Genotype
MGI:4413348
cn20
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Rnf2tm1Mvi/Rnf2tm1Mvi
Genetic
Background
involves: 129S/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Rnf2tm1Mvi mutation (0 available); any Rnf2 mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• E11.5 neural precursor cells cultured for 9 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• E17.5 neural precursor cells cultured for 3 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• neuronal precursor cells treated with tamoxifen and subjected to growth factor deprivation at the late stage (12 days in culture) exhibit reduced astrocyte differentiation compared with similarly treated control Rnf2tm1Mvi cells
• at P2.5, tamoxifen-treated mice exhibit reduced astrocytic differentiation compared with similarly treated control Rnf2tm1Mvi cells

cellular
• E11.5 neural precursor cells cultured for 9 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• E17.5 neural precursor cells cultured for 3 days in the presence of S33Y beta-catenin and tamoxifen exhibit enhanced neuronal differentiation compared with similarly treated control Rnf2tm1Mvi cells
• neuronal precursor cells treated with tamoxifen and subjected to growth factor deprivation at the late stage (12 days in culture) exhibit reduced astrocyte differentiation compared with similarly treated control Rnf2tm1Mvi cells
• at P2.5, tamoxifen-treated mice exhibit reduced astrocytic differentiation compared with similarly treated control Rnf2tm1Mvi cells




Genotype
MGI:4819716
cn21
Allelic
Composition
Pkd1tm1Gztn/Pkd1tm1Gztn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S/Sv * 129S7/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pkd1tm1Gztn mutation (0 available); any Pkd1 mutation (99 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
renal/urinary system
• tamoxifen treated mice develop kindey cysts
• however, treatment with Genz-123346 inhibits cystogenesis
• tamoxifen-treated mice exhibit progressive renal function decline over 4 to 5 weeks
• however, treament with Genz-123346 improves kidney fucntion

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
polycystic kidney disease 1 DOID:0110858 OMIM:173900
J:162080




Genotype
MGI:5551391
cn22
Allelic
Composition
Chuktm1Lex/Chuktm1Lex
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S/Sv * 129S/SvEvBrd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Chuktm1Lex mutation (1 available); any Chuk mutation (6 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• following tamoxifen-treatment, mouse embryonic fibroblasts (MEFs) exhibit random migration in response to an HMGB1 gradient unlike wild-type cells
• 180 minutes after exposure to HMGB1, tamoxifen-treated MEFs exhibit reduced migration velocity compared with wild-type mice
• following tamoxifen-treatment, MEFs exhibit impaired chemotaxis in response to HMGB1 compared with wild-type cells that is not rescued by Nfkb2
• however, chemotaxis in response to PDGF is normal




Genotype
MGI:4839528
cn23
Allelic
Composition
Epotm1Knni/Epotm1Knni
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Epotm1Knni mutation (0 available); any Epo mutation (28 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• a decrease in the CD71- Ter119+ population, an intermediate erythroid progenitor stage in the bone marrow
• 50 days after tamoxifen induction with a subcutaneous pellet
• 50 days after tamoxifen induction with a subcutaneous pellet
• 50 days after tamoxifen induction with a subcutaneous pellet




Genotype
MGI:4413346
cn24
Allelic
Composition
Ezh2tm1Yugo/Ezh2tm1Yugo
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: 129S/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ezh2tm1Yugo mutation (1 available); any Ezh2 mutation (53 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• following exposure to tamoxifen, neuronal differentiation in culture induced by FGF2 deprivation or S33Y beta-catenin expression is enhanced compared to in similarly treated control mice
• following exposure to tamoxifen, the reduction in Ngn1+ cells in the late neurogenic phase (E17.5) is suppressed compared to in similarly treated control mice

cellular
• following exposure to tamoxifen, neuronal differentiation in culture induced by FGF2 deprivation or S33Y beta-catenin expression is enhanced compared to in similarly treated control mice
• following exposure to tamoxifen, the reduction in Ngn1+ cells in the late neurogenic phase (E17.5) is suppressed compared to in similarly treated control mice




Genotype
MGI:4430332
cn25
Allelic
Composition
Foxl2tm2.1Tre/Foxl2tm2.1Tre
Gt(ROSA)26Sortm9(cre/ESR1)Arte/?
Genetic
Background
involves: 129S/Sv * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxl2tm2.1Tre mutation (0 available); any Foxl2 mutation (3 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• almost entire structure is affected by 3 weeks following tamoxifen treatment
• instead of normal granulosa cells, cells with morphological characteristics of Sertoli cells (prominent basal lamina, tripartite nuclei, numerous veil-like cytoplasmic extensions pointing toward lumen) are observed 3 weeks following tamoxifen treatment; Leydig cell markers are also detected in mutant gonads
• one week after start of tamoxifen treatment, many granulosa cells start to transdifferentiate into Sertoli-like cells; unlike normal granulosa cells, these abnormal cells do not undergo apoptosis at end of a follicle life cycle and are still present after 6 months
• 3 weeks following tamoxifen treatment, typical follicular structure of ovary resembles seminiferous tubules of testis
• 8-week-old female mice treated for 5 days with tamoxifen and analysed 3 weeks later exhibit gonadal sex reversal

endocrine/exocrine glands
• almost entire structure is affected by 3 weeks following tamoxifen treatment
• instead of normal granulosa cells, cells with morphological characteristics of Sertoli cells (prominent basal lamina, tripartite nuclei, numerous veil-like cytoplasmic extensions pointing toward lumen) are observed 3 weeks following tamoxifen treatment; Leydig cell markers are also detected in mutant gonads
• one week after start of tamoxifen treatment, many granulosa cells start to transdifferentiate into Sertoli-like cells; unlike normal granulosa cells, these abnormal cells do not undergo apoptosis at end of a follicle life cycle and are still present after 6 months
• 3 weeks following tamoxifen treatment, typical follicular structure of ovary resembles seminiferous tubules of testis




Genotype
MGI:5462060
cn26
Allelic
Composition
Nodaltm1.1Ysa/Nodaltm1.1Ysa
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Nodaltm1.1Ysa mutation (0 available); any Nodal mutation (15 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• following tamoxifen treatment at E10.5 expression analysis indicates a delay in germ cell differentiation at E14.5 that is no longer detectable by E16.5

reproductive system
• following tamoxifen treatment at E10.5 expression analysis indicates a delay in germ cell differentiation at E14.5 that is no longer detectable by E16.5




Genotype
MGI:5523516
cn27
Allelic
Composition
Sptlc2tm1Yhir/Sptlc2tm1Yhir
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Sptlc2tm1Yhir mutation (1 available); any Sptlc2 mutation (164 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• 48 hours after tamoxifen treatment, mice exhibit slight lymphoid necrosis in the cortex of the thymus compared with control mice
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the thymus, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice
• 48 and 72 hours after tamoxifen treatment
• slight in tamoxifen treated mice at 48 hours of both erythroid and myeloid cells
• further decrease after 72 hours in tamoxifen-treated mice
• 72 hours after tamoxifen treatment
• 72 hours after tamoxifen treatment
• 72 hours after tamoxifen treatment
• 72 hours after tamoxifen treatment
• 48 and 72, but not 24, hours after tamoxifen treatment
• 48 and 72, but not 24, hours after tamoxifen treatment
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the spleen, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice
• 72 hours after tamoxifen treatment

digestive/alimentary system
• decreased at 72 hours in tamoxifen-treated mice
• 72 hours after tamoxifen treatment, mice exhibit atrophy of the small and large intestine mucosa with sloughing of mucosal epithelial cells and/or necrotic decries in the crypts compared with control mice
• 24 and 48 hours after tamoxifen treatment, mice exhibit several single cell necroses in the epithelia of small and large intestine crypts unlike control mice
• 24 and 48 hours after tamoxifen treatment, mice exhibit several single cell necroses in the epithelia of small and large intestine crypts unlike control mice
• 48 hours after tamoxifen treatment, mice exhibit increased single cell necroses at the base of villi in the small intestine compared with control mice
• 72 hours after tamoxifen treatment, mice exhibit atrophy of the stomach mucosa predominantly in the pyloric region and characterized by exfoliation of necrotic epithelial cells into the gastric lumen and thinning of the gastric epithelial cells, especially the gastric gland epithelium, compared with control mice

homeostasis/metabolism
• in tamoxifen-treated mice
• increased total protein in tamoxifen-treated mice
• total and albumin to globulin ratio in tamoxifen-treated mice

cellular
• 24 and 48 hours after tamoxifen treatment, mice exhibit several single cell necroses in the epithelia of small and large intestine crypts unlike control mice
• 48 hours after tamoxifen treatment, mice exhibit increased single cell necroses at the base of villi in the small intestine compared with control mice
• 48 hours after tamoxifen treatment, mice exhibit slight lymphoid necrosis in the cortex of the thymus compared with wild-type mice
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the thymus and spleen, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice

integument
• slight at 72 hours in tamoxifen-treated mice

endocrine/exocrine glands
• decreased at 72 hours in tamoxifen-treated mice
• 24 and 48 hours after tamoxifen treatment, mice exhibit several single cell necroses in the epithelia of small and large intestine crypts unlike control mice
• 24 and 48 hours after tamoxifen treatment, mice exhibit several single cell necroses in the epithelia of small and large intestine crypts unlike control mice
• increased adrenal gland weight at 72 hours after tamoxifen treatment
• 48 hours after tamoxifen treatment, mice exhibit slight lymphoid necrosis in the cortex of the thymus compared with control mice
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the thymus, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice
• 48 and 72 hours after tamoxifen treatment
• slight at 72 hours in tamoxifen-treated mice

immune system
• 48 hours after tamoxifen treatment, mice exhibit slight lymphoid necrosis in the cortex of the thymus compared with control mice
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the thymus, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice
• 48 and 72 hours after tamoxifen treatment
• 72 hours after tamoxifen treatment
• 48 and 72, but not 24, hours after tamoxifen treatment
• 72 hours after tamoxifen treatment, mice exhibit lymphoid necrosis in the spleen, predominantly in the periarterial lymphoid sheaths, with lymphoid depletion compared with control mice
• 72 hours after tamoxifen treatment




Genotype
MGI:5444639
cn28
Allelic
Composition
Sh2d1atm2.1Cpt/Y
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Sh2d1atm2.1Cpt mutation (0 available); any Sh2d1a mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• tamoxifen-treated mice exhibit functionally active NK T cells
• following exposure to NP-KLH with alpha-GalCer, germinal center B cells from tamoxifen-treated mice fail to exhibit an increase in numbers unlike in wild-type mice
• tamoxifen-treated mice exhibit reduced late primary antibody response on transfer of OT-II CD4+ T cells compared with wild-type
• following immunization with NP-KLH and alpha-GalCer, tamoxifen-treated mice exhibit reduced NP-specific IgG that is more severe than in Sh2d1atm1Cpt homozygotes
• following exposure to NP-KLH with alpha-GalCer, tamoxifen treated mice produce less anti-NP-IgM compared with wild-type mice

hematopoietic system
• following exposure to NP-KLH with alpha-GalCer, germinal center B cells from tamoxifen-treated mice fail to exhibit an increase in numbers unlike in wild-type mice
• following immunization with NP-KLH and alpha-GalCer, tamoxifen-treated mice exhibit reduced NP-specific IgG that is more severe than in Sh2d1atm1Cpt homozygotes
• following exposure to NP-KLH with alpha-GalCer, tamoxifen treated mice produce less anti-NP-IgM compared with wild-type mice




Genotype
MGI:5547377
cn29
Allelic
Composition
Nr4a2tm1.1Pcn/Nr4a2tm1.1Pcn
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Nr4a2tm1.1Pcn mutation (0 available); any Nr4a2 mutation (25 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• increased under Th1-, Th17- and induced regulatory T cell-skewing conditions following tamoxifen-treatment
• reduced under Th17-skewing conditions following tamoxifen-treatment
• reduced regulatory T cell differentiation under induced regulatory T cell-skewing conditions following tamoxifen-treatment

hematopoietic system
• increased under Th1-, Th17- and induced regulatory T cell-skewing conditions following tamoxifen-treatment
• reduced under Th17-skewing conditions following tamoxifen-treatment
• reduced regulatory T cell differentiation under induced regulatory T cell-skewing conditions following tamoxifen-treatment




Genotype
MGI:5439659
cn30
Allelic
Composition
Bap1tm1.1Geno/Bap1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bap1tm1.1Geno mutation (0 available); any Bap1 mutation (15 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• tamoxifen treatment induces mild but progressive hematological defects




Genotype
MGI:5439657
cn31
Allelic
Composition
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bap1tm1.1Geno mutation (0 available); any Bap1 mutation (15 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• multifocal necrosis after tamoxifen treatment

neoplasm
• changes in leukocyte numbers are consistent with a chronic myelomonocytic leukemia (CMML)-like disease
• transplantation of bone marrow cells into lethally irradiated congenic wild-type mice followed by tamoxifen treatment also results in a CMML-like disease

hematopoietic system
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
• 4 weeks after the last tamoxifen injection
• develop severe progressive anemia after tamoxifen treatment
• signs of erythroid dysplasia after tamoxifen treatment
• prominent basophilic stippling after tamoxifen treatment
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with ineffective erythropoiesis
• after tamoxifen treatment
• after tamoxifen treatment
• bilobed granulocytes after tamoxifen treatment
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
• 4 weeks after the last tamoxifen injection
• detected as early as 1 week after the last tamoxifen treatment
• giant platelets detected after tamoxifen treatment
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
• 4 weeks after the last tamoxifen injection
• in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• seen in all mice 4 weeks after the last tamoxifen injection
• cells taken from tamoxifen treated mice fail to reconstitute the bone marrow of lethally irradiated congenic wild-type mice
• cultured cells collected 1 month after the last tamoxifen treatment produce fewer colonies and replated cells do not produce well formed colonies

immune system
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment
• at 4 weeks after the last tamoxifen injection peripheral blood shows cytological features consistent with myelodysplasia
• increase in the number of lineage-negative ScaI? c-Kit+ myeloid progenitor cells in the spleen and bone marrow as early as 2 weeks after the last tamoxifen treatment
• atypical immature cells with myelomonocytic features detected after tamoxifen treatment
• expansion of the myeloid lineage in the spleen, lymph nodes and bone marrow at 4 weeks after the last tamoxifen injection
• bilobed granulocytes after tamoxifen treatment
• hypersegmented and hyposegmented neutrophils after tamoxifen treatment
• 4 weeks after the last tamoxifen injection
• elevated total leukocyte numbers at 4 weeks after the last tamoxifen injection
• 4 weeks after the last tamoxifen injection
• seen in all mice 4 weeks after the last tamoxifen injection

homeostasis/metabolism
• microthrombi in the heart after tamoxifen treatment

muscle
• multifocal necrosis after tamoxifen treatment

cardiovascular system
• multifocal necrosis after tamoxifen treatment
• neutrophilic inflammation and infiltration of myeloblastic cells after tamoxifen treatment

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
myelodysplastic syndrome DOID:0050908 OMIM:614286
J:187380




Genotype
MGI:5306649
cn32
Allelic
Composition
Cbx8tm1Hko/Cbx8tm1Hko
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cbx8tm1Hko mutation (1 available); any Cbx8 mutation (12 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• MigR1-MLL-AF9-transformed and tamoxifen-treated bone marrow cells exhibit impaired initiation and maintenance of leukemic transformation

hematopoietic system
N
• tamoxifen-treated mice exhibit normal hematopoiesis, long-term hematopoietic stem cell maintenance, and stem and progenitor cell function




Genotype
MGI:4946835
cn33
Allelic
Composition
Ciao3tm1.1Fsl/Ciao3tm1.1Fsl
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ciao3tm1.1Fsl mutation (1 available); any Ciao3 mutation (5 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all mice die within 5 days of tamoxifen treatment




Genotype
MGI:5496427
cn34
Allelic
Composition
Eef1a1tm2Arge/Eef1a1+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Eef1a1tm2Arge mutation (0 available); any Eef1a1 mutation (54 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• leukemia-initiating cells plated in methylcellulose cultures in the presence of tamoxifen exhibit decreased blast colony number and loss of blast colony formation due to increased apoptosis compared with control cells




Genotype
MGI:5461543
cn35
Allelic
Composition
Cd28tm1.1Huen/Cd28tm1.1Huen
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd28tm1.1Huen mutation (0 available); any Cd28 mutation (29 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• after 1 week, tamoxifen-treated mice exhibit decreased regulatory T cell number compared with control mice that is thymus independent and associated with reduced cell proliferation
• regulatory T cells from tamoxifen-treated mice exhibit reduced suppression function and a 2-fold reduction in proliferation compared with wild-type cells

hematopoietic system
• after 1 week, tamoxifen-treated mice exhibit decreased regulatory T cell number compared with control mice that is thymus independent and associated with reduced cell proliferation
• regulatory T cells from tamoxifen-treated mice exhibit reduced suppression function and a 2-fold reduction in proliferation compared with wild-type cells




Genotype
MGI:5444641
cn36
Allelic
Composition
Sh2d1atm2.1Cpt/Sh2d1atm2.1Cpt
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Sh2d1atm2.1Cpt mutation (0 available); any Sh2d1a mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• tamoxifen-treated mice exhibit functionally active NK T cells
• following exposure to NP-KLH with alpha-GalCer, germinal center B cells from tamoxifen-treated mice fail to exhibit an increase in numbers unlike in wild-type mice
• tamoxifen-treated mice exhibit reduced late primary antibody response on transfer of OT-II CD4+ T cells compared with wild-type
• following immunization with NP-KLH and alpha-GalCer, tamoxifen-treated mice exhibit reduced NP-specific IgG that is more severe than in Sh2d1atm1Cpt homozygotes
• following exposure to NP-KLH with alpha-GalCer, tamoxifen treated mice produce less anti-NP-IgM compared with wild-type mice

hematopoietic system
• following exposure to NP-KLH with alpha-GalCer, germinal center B cells from tamoxifen-treated mice fail to exhibit an increase in numbers unlike in wild-type mice
• following immunization with NP-KLH and alpha-GalCer, tamoxifen-treated mice exhibit reduced NP-specific IgG that is more severe than in Sh2d1atm1Cpt homozygotes
• following exposure to NP-KLH with alpha-GalCer, tamoxifen treated mice produce less anti-NP-IgM compared with wild-type mice




Genotype
MGI:5502351
cn37
Allelic
Composition
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Nabp2tm1.1Kkha mutation (1 available); any Nabp2 mutation (20 available)
phenotype observed in females
phenotype observed in males
N normal phenotype

Testicular degeneration in Nabp2tm1.1Kkha/Nabp2tm1.1Kkha Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+ mice

liver/biliary system
• in some tamoxifen-treated mice

mortality/aging

reproductive system
N
• tamoxifen-treated female mice exhibit normal fertility
• premature sloughing from the supporting Sertoli cells in tamoxifen-treated mice
• due to apoptosis and premature sloughing from the supporting Sertoli cells in tamoxifen-treated mice
• decreased elongated spermatids
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• bilateral degeneration; tubules showed degenerate, sometimes vacuolated, or necrotic spermatogenic cells, the latter with pyknotic nuclei and hypereosinophilic cytoplasm, or apoptotic body formation in tamoxifen-treated mice
• from tamoxifen-treated mice with longer intervals between litters
• in tamoxifen-treated mice

neoplasm
• splenic and metastatic B lymphomas, T cell lymphoma in thymus, hepatocellular carcinoma and B or T lymphoblastic leukemia in 11 of 35 of tamoxifen-treated mice
• in thymus of some tamoxifen-treated mice
• in some tamoxifen-treated mice
• B or T lymphoblastic leukemia in some tamoxifen-treated mice
• splenic and metastatic B lymphomas in some tamoxifen-treated mice

cellular
• premature sloughing from the supporting Sertoli cells in tamoxifen-treated mice
• due to apoptosis and premature sloughing from the supporting Sertoli cells in tamoxifen-treated mice
• decreased elongated spermatids
• in irradiated tamoxifen-treated mice
• in tamoxifen-treated mice
• tamoxifen-treated mice exposed to ionizing radiation exhibit distended crypt lumina lined by attenuated enterocytes, desquamated necrotic cellular debris and a small increase of cells near deep crypts with apoptotic bodies
• however, blood counts are normal in irradiated tamoxifen-treated mice
• in tamoxifen-treated mice

growth/size/body
• at E14.5 and E18.5

digestive/alimentary system
• tamoxifen-treated mice exposed to ionizing radiation exhibit distended crypt lumina lined by attenuated enterocytes, desquamated necrotic cellular debris and a small increase of cells near deep crypts with apoptotic bodies

immune system
• in irradiated tamoxifen-treated mice

endocrine/exocrine glands
• in irradiated tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice
• bilateral degeneration; tubules showed degenerate, sometimes vacuolated, or necrotic spermatogenic cells, the latter with pyknotic nuclei and hypereosinophilic cytoplasm, or apoptotic body formation in tamoxifen-treated mice
• in thymus of some tamoxifen-treated mice

hematopoietic system
N
• blood counts are normal in irradiated tamoxifen-treated mice
• in irradiated tamoxifen-treated mice

homeostasis/metabolism




Genotype
MGI:5441571
cn38
Allelic
Composition
Hsp90aa1tm1.2Udon/Hsp90aa1tm1.2Udon
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6 * C57BL/6NTac * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Hsp90aa1tm1.2Udon mutation (0 available); any Hsp90aa1 mutation (5 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• in tamoxifen-treated mice
• beyond the pachytene stage in tamoxifen-treated mice
• in tamoxifen-treated mice
• one third normal in tamoxifen-treated mice
• in tamoxifen-treated mice
• in tamoxifen-treated mice

cellular
• in tamoxifen-treated mice
• beyond the pachytene stage in tamoxifen-treated mice

endocrine/exocrine glands
• in tamoxifen-treated mice
• one third normal in tamoxifen-treated mice
• in tamoxifen-treated mice




Genotype
MGI:5464119
cn39
Allelic
Composition
Ddx5tm1.1Arte/Ddx5tm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6N * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ddx5tm1.1Arte mutation (2 available); any Ddx5 mutation (9 available)
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• hematopoietic cells from tamoxifen-treated mice are more sensitive to gamma-irradiation compared with control cells




Genotype
MGI:5912012
cn40
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Pkn2tm1c(KOMP)Wtsi/Pkn2tm1c(KOMP)Wtsi
Genetic
Background
involves: C57BL/6N * C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pkn2tm1c(KOMP)Wtsi mutation (0 available); any Pkn2 mutation (12 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
embryo
• following tamoxifen treatment
• tamoxifen treatment at E7.5 results in axial turning defects in most mice at E9.5
• tamoxifen treatment at E6.5 reproduces the gross phenotypes seen in germline null mice
• loss of branchial arches following tamoxifen treatment
• decrease in cephalic mesoderm at E10 in embryos treated with tamoxifen at E8.0
• tamoxifen treatment at E6.5 results in collapse of the mesenchyme

cardiovascular system
• vascular disintegration following tamoxifen treatment
• at E10 in embryos treated with tamoxifen at E8.0

cellular
• in MEFs tamoxifen treatment results in an accumulation of cells in G1/G0 and loss of S-phase and mitotic cells
• in pharyngeal mesodermal cells at E10, 48h past tamoxifen treatment
• however mitotic indices in branchial arch, neural tube, and heart cells are similar to controls
• following tamoxifen treatment
• reduced MEF cell growth following tamoxifen treatment
• however, tamoxifen treatment of embryonic stem cells does not alter cell growth

craniofacial
• loss of branchial arches following tamoxifen treatment




Genotype
MGI:5444174
cn41
Allelic
Composition
Pi4katm1.1Arte/Pi4katm1.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pi4katm1.1Arte mutation (0 available); any Pi4ka mutation (80 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
endocrine/exocrine glands
• parietal cell degeneration of glandular mucosa following tamoxifen-induction

mortality/aging
• within days of tamoxifen-induction

digestive/alimentary system
• following tamoxifen-induction, mucosal epithelial cells of the mucosae of the stomach and the small and large intestines exhibit widespread degeneration and necrosis compared with control mice
• distended and filled with yellowish clear fluid following tamoxifen-induction
• following tamoxifen-induction, mice exhibit mucosal epithelial degeneration of cecal mucosa compared with control mice
• following tamoxifen-induction, mice exhibit mucosal epithelial degeneration of duodenal mucosa compared with control mice
• following tamoxifen-induction, mice exhibit ulceration of nonglandular mucosa and parietal cell degeneration of glandular mucosa compared with control mice
• parietal cell degeneration of glandular mucosa following tamoxifen-induction
• distended and filled with food following tamoxifen-induction




Genotype
MGI:5614626
cn42
Allelic
Composition
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Ripk3tm1Arte/Ripk3tm1Arte
Genetic
Background
involves: C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Ripk3tm1Arte mutation (0 available); any Ripk3 mutation (24 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
digestive/alimentary system
• mice treated with tamoxifen exhibit degeneration of intestinal crypts
• mice treated with tamoxifen exhibit villous blunting
• mice treated with tamoxifen exhibit villous fusion
• mice treated with tamoxifen develop diarrhea
• mice treated with tamoxifen exhibit increased apoptosis in the small intestine
• mice treated with tamoxifen exhibit segmental, submucosal edema in the large intestine
• mice treated with tamoxifen exhibit mild enteritis

endocrine/exocrine glands
• mice treated with tamoxifen exhibit degeneration of intestinal crypts
• mice treated with tamoxifen show thymic atrophy

growth/size/body
• mice treated with tamoxifen lose between 13 and 28% of their body weight after 6 to 7 days

hematopoietic system
• mice treated with tamoxifen show thymic atrophy
• mice treated with tamoxifen exhibit pyknotic and karyorrhectic lymphocytes in secondary lymphoid organs

homeostasis/metabolism
• mice treated with tamoxifen exhibit segmental, submucosal edema in the large intestine

immune system
• mice treated with tamoxifen exhibit mild enteritis
• mice treated with tamoxifen show thymic atrophy
• mice treated with tamoxifen exhibit pyknotic and karyorrhectic lymphocytes in secondary lymphoid organs

mortality/aging
N
• mice treated with tamoxifen do not show signs of morbidity after 5 days




Genotype
MGI:5444176
cn43
Allelic
Composition
Pi4katm2.1Arte/Pi4ka+
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pi4katm2.1Arte mutation (0 available); any Pi4ka mutation (80 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• 12 days following tamoxifen-treatment in male mice
• however, female mice remain normal

digestive/alimentary system
• following tamoxifen-treatment, male mice exhibit similar observations as in homozygous conditional knock-ins but with lower severity

behavior/neurological
• following tamoxifen-treatment in male mice
• however, female mice remain normal

growth/size/body
• following tamoxifen-treatment in male mice
• however, female mice remain normal

hematopoietic system
• following tamoxifen-treatment, one female mouse exhibited a black focal mild discoloration of the spleen

integument
• poor coat condition following tamoxifen-treatment in male mice
• however, female mice remain normal

immune system
• following tamoxifen-treatment, one female mouse exhibited a black focal mild discoloration of the spleen




Genotype
MGI:5444175
cn44
Allelic
Composition
Pi4katm2.1Arte/Pi4katm2.1Arte
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
Genetic
Background
involves: C57BL/6NTac
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm9(cre/ESR1)Arte mutation (3 available); any Gt(ROSA)26Sor mutation (497 available)
Pi4katm2.1Arte mutation (0 available); any Pi4ka mutation (80 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• within 10 to 11 days of tamoxifen-induction

digestive/alimentary system
• following tamoxifen-induction, mice exhibit widespread mucosal epithelial degeneration more so in the small and large intestines and less in the stomach compared with control mice
• however, mice do not exhibit a distended intestine morphology
• focal atypical hyperplasia of mucosal crypts with small clusters of enlarged atypical crypts lined by tall dysplastic basophilic epithelial cells in the small intestine following tamoxifen-induction
• following tamoxifen-induction, mice exhibit swollen and basophilic surface epithelial cells in the large intestine compared with control mice
• loss of mucosal crypts in some areas of the large intestine following tamoxifen-induction
• following tamoxifen-induction, mice exhibit swollen villous epithelial cells with excessive vacuoles in the small intestine compared with control mice
• following tamoxifen-induction
• following tamoxifen-induction, mice exhibit loose or discolored intestine content

growth/size/body
• thin following tamoxifen-treatment

behavior/neurological
• in moribund mice following tamoxifen-induction
• following tamoxifen-treatment

integument
• in moribund mice following tamoxifen-induction
• poor coat condition following tamoxifen-treatment

endocrine/exocrine glands
• loss of mucosal crypts in some areas of the large intestine following tamoxifen-induction
• focal atypical hyperplasia of mucosal crypts with small clusters of enlarged atypical crypts lined by tall dysplastic basophilic epithelial cells in the small intestine following tamoxifen-induction





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/05/2019
MGI 6.14
The Jackson Laboratory